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Introduction: This study aimed to describe treatment changes (discontinuation, switching, and therapy add-on)
following the initiation of biologic or nonbiologic oral disease-modifying antirheumatic drugs (DMARDs) in psoriatic
arthritis (PsA) patients.
Methods: Adult patients with ≥2 PsA diagnoses from physician office visits, initiated on a biologic or nonbiologic
oral DMARD, were selected from the Truven Health Analytics MarketScan® Research Database (2005 to 2009).
Patients were required to have continuous insurance coverage ≥6 months prior to and ≥12 months post index
date (first prescription fill date). Treatment discontinuation, treatment switch, and therapy add-on were captured
over the 1 year period following the index date. Treatment changes were described separately for patients initiated
on nonbiologic and biologic DMARDs.
Results: A total of 1,698 and 3,263 patients were initiated on an oral nonbiologic DMARD and biologic DMARD
respectively. For patients initiated on nonbiologic DMARDs, 69% had ≥1 therapy change over the 12 month study
period (median time 85 days). Among patients who had a therapy change, 83% discontinued, 29% switched
therapy (64% switched to a biologic DMARD), and 25% had a therapy add-on (76% added-on with a biologic
DMARD). For patients initiated on a biologic DMARD, 46% had ≥1 therapy change (median time 110 days). Among
patients who had a therapy change, 100% discontinued, 25% switched therapy (92% switched to another biologic
DMARD), and 7% had a therapy add-on with a nonbiologic DMARD.
Conclusion: This study suggests that PsA patients newly initiated on a nonbiologic/biologic DMARD do not remain
on the index treatment for a long period of time. A better understanding of factors related to these early treatment
changes in PsA patients is needed.Introduction
Psoriatic arthritis (PsA), an idiopathic, chronic, and often
progressive immune-mediated autoinflammatory arthritis,
affects peripheral and axial joints, nails and entheses, and
is typically accompanied by psoriatic skin lesions [1,2].
Although phenotypically heterogeneous, PsA symptoms
typically include joint pain, stiffness, swelling, nail pso-
riasis, dactylitis and generalized fatigue [1,3]. In the United
States, the prevalence of PsA is estimated to be between
0.10% and 0.25% of the overall population [1].* Correspondence: jcurtis@uab.edu
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unless otherwise stated.The immediate treatment goals in PsA include mitiga-
ting joint pain and swelling, skin lesions, disease progres-
sion, and systemic sequelae [3,4]. The ultimate treatment
goal - disease remission - is characterized by the absence
of clinically discernible disease activity and the potential
for joint healing [4,5]. Pharmacotherapy for PsA encom-
passes nonsteroidal anti-inflammatory drugs (NSAIDs)
and intra-articular corticosteroid injections to manage
musculoskeletal pain, stiffness, and swelling, as well as
nonbiologic and biologic disease-modifying antirheumatic
drugs (DMARDs), which have the potential to attenuate
joint damage and promote disease remission [6].
American Academy of Dermatology (AAD) and the
European League against Rheumatism (EULAR) recom-
mended treatment guidelines for PsA advocate a stepwiseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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involvement, and the extent of inflammation [6-8]. Mild
PsA is typically treated with NSAIDs or intra-articular
corticosteroid injections [6,9]. If a satisfactory response is
not achieved after 3 months, or if there is evidence of per-
sistent inflammation or of erosive or polyarticular disease,
the guidelines suggest the option of using a traditional oral
nonbiologic DMARD, such as methotrexate (MTX) [7-9].
Yet the clinical data supporting the use of MTX as a
disease-modifying agent in PsA remain limited [10-13]. In
a recent double-blind, randomized, placebo-controlled
study in patients with active PsA, MTX treatment failed
to improve objective assessments of synovitis or of tender
and swollen joint counts, despite improvements in skin
scores and patients’ and assessors’ global evaluations [13].
If traditional oral nonbiologic DMARDs cannot properly
control the signs and symptoms of PsA, the guidelines
suggest the use of biologics such as etanercept and adali-
mumab [7]. Biologics have demonstrated robust efficacy
in PsA to date [2]. A recent study investigating potential
effects of MTX co-medication with TNF inhibitor
(TNFi) - a type of biologic - on treatment response and
persistence in PsA patients found a benefit in terms of
treatment persistence of using MTX concomitantly with
another TNFi [14]. Despite the treatment guidelines and
clinical studies that demonstrate the benefits and risks
of oral DMARDs and biologics in PsA, it remains un-
clear how physicians generally approach the manage-
ment of PsA. The main objective of this study was to
describe treatment patterns (treatment discontinuation,
treatment switches, and therapy add-ons) for PsA pa-
tients newly treated with oral nonbiologic or biologic
DMARDs in a real-world setting.
Methods
Data source
This retrospective study used data from the US-based
Truven Health Analytics MarketScan® Research Data-
bases, acquired between the first quarter (Q1) of 2005
and Q4 of 2009. The database included approximately
25 million individuals, annually covered by 130 health
plans and self-insured employers. The database covers
all census regions in the US and contains information
on patient demographics, enrollment history, claims for
inpatient and outpatient medical services, and pharmacy
claims. Patient data were de-identified and comply with
the patient confidentiality requirements of the Health
Insurance Portability and Accountability Act. Therefore,
Institutional Review Board approval was not required.
Sample selection and construction
Adult PsA patients newly treated with oral nonbiologic
DMARDs or biologic DMARDs were selected in this
study. Patients initiated on nonbiologic DMARDs wererequired to be naïve to any biologic or nonbiolo-
gic DMARDs recommended for PsA before the first
oral nonbiologic DMARD initiation date (index date).
Biologic DMARD patients may have been pre-treated
with a nonbiologic DMARD before the index date. Adult
patients with active PsA were defined as those who were
at least 18 years of age at the index date and had at least
two physician PsA diagnoses (ICD-9-CM code: 696.0x)
from two separate office visits over the 18-month obser-
vation period (that is, at least one diagnosis during the
6-month period before the index date (baseline period),
and at least one during the 12-month period after the
index date (study period)). Patients who did not have
at least a 6-month baseline period or 12-month study
period in the database were excluded from the study.
Oral nonbiologic DMARDs considered included MTX,
cyclosporine, leflunomide, mycophenolate, gold com-
pounds, antimalarials, minocycline, penicillamine, azathio-
prine, and sulfasalazine. Due to the wide use of MTX in
PsA, a subgroup analysis was conducted for patients
newly initiated on MTX. Biologic DMARDs in the study
included etanercept, infliximab, golimumab, certolizumab
pegol, adalimumab, anakinra, abatacept, and rituximab
based on clinical use although some do not have indica-
tion in PsA. Patients were excluded if they had a diagnosis
of ankylosing spondylitis (AS) (ICD-9-CM code: 720.0x)
at any time before the index date.
Patients newly initiated on oral nonbiologic DMARDs
and biologic DMARDs were analyzed separately during
the baseline and study period. These two samples were
not mutually exclusive. For example, a patient initiating
therapy on an oral nonbiologic DMARD who later
switched to a biologic DMARD could be included in both
samples if the two initiation dates met all the aforemen-
tioned selection criteria. However, this had no impact on
the study analyses and interpretation of the results, given
that the two samples were analyzed independently, and no




As defined subsequently, therapy change was defined as
the discontinuation of the index treatment (that is, the
nonbiologic or biologic DMARD initiated at the index
date), a switch from the index treatment to another
treatment, or a therapy add-on. Patients may have had
more than one therapy change over the study period.
Discontinuation
Treatment discontinuation was defined as the first oc-
currence of a treatment interruption of at least 60 con-
secutive days between the end of the drug supply for a
prescription of the index treatment and the beginning of
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of the one-year study period, whichever occurred first.
Treatment switch
A treatment switch was defined as the initiation of a treat-
ment other than the index DMARD within 60 days of the
interruption of the index treatment. For patients initiated
on an oral nonbiologic or on a biologic DMARD, other
nonbiologic (either oral or subcutaneous), or biologic
DMARDs were considered as switch treatments. Ad-
ditionally, as patients initiated on a biologic could have
used nonbiologic DMARDs prior to the index date, the
nonbiologic treatment (either oral or subcutaneous) to
which the patient was being switched could not have been
taken during the 60-day period prior to the switch date.
For patients who initiated concomitant treatments on the
index date, any treatments used at the index date were not
considered potential switch treatments. Treatment swit-
ches were captured from the index date up to 60 days
after the first discontinuation of the index treatment, or
up to the end of the study period, whichever occurred
first. All treatments initiated within the 60 days following
treatment discontinuation were reported as a switch.
Therapy add-on
Therapy add-on was defined as the use of a DMARD
treatment other than the treatment used at the index date
for at least 28 consecutive days before the discontinuation
of the index therapy. For patients initiated on an oral
nonbiologic DMARD, the use of any other nonbiologic
DMARDs (either oral or subcutaneous), or biologic
DMARDs were considered potential therapy add-on treat-
ments. For patients initiated on a biologic DMARD,
nonbiologic DMARDs (either oral or subcutaneous) were
considered potential therapy add-on treatment agents.
Additionally, as patients who were initiated on a biologic
DMARD may have used nonbiologic DMARDs prior to
the index date, the DMARD used for add-on was required
to have not been taken during the 60-day period prior to
the start of therapy add-on. For patients who initiated
concomitant treatments at the index date, any treatments
used at the index date were not considered potential
add-on treatments. Add-on rates were captured over the
period spanning from the index date up to the disconti-
nuation of the index treatment, or until the end of the
study period, whichever occurred first.
Sensitivity analyses
It may be difficult in claims data to ensure that the
selected PsA patients have been accurately diagnosed for
PsA, particularly since some of the core symptoms of PsA
are also present in AS or rheumatoid arthritis (RA). How-
ever, AS and RA may similarly lead to patient misclas-
sification as a PsA diagnosis, or may have overlappingfeatures with PsA. As a result, two sensitivity analyses
were performed to test the robustness of our findings; (1)
as AS patients were excluded in the main analysis, the first
sensitivity analysis was conducted without excluding pa-
tients with AS, and (2) as RA patients were included in
the main analysis, the second sensitivity analysis excluded
patients diagnosed with RA.
Additionally, as a supplemental sensitivity analysis,
discontinuation was defined as the first occurrence of a
treatment interruption of at least 90 consecutive days
between the end of the drug supply (for a prescription of
the index treatment) and the beginning of a next pre-
scription (for the index treatment), or the end of the
one-year study period, whichever occurred first.
Statistical analyses
Baseline data were analyzed descriptively and reported
separately for patients initiated on an oral nonbiologic
DMARD, for patients initiated on a biologic DMARD,
and for the subgroup of patients initiated on MTX.
Reported characteristics included demographics (age,
gender), treatment characteristics, specialist encounters,
and comorbidities. The Charlson comorbidity index
(CCI) adapted by Deyo for administrative databases was
used to assess the level of comorbidity associated with
each PsA cohort [15].
Treatment patterns were reported separately for pa-
tients initiated on an oral nonbiologic DMARD, on a
biologic DMARD, and for patients from the MTX
subgroup. The proportions of patients who discontinued
the index treatment, switched to another DMARD, had
a therapy add-on, or had any therapy changes over the
12-month study period were reported. Additionally, the
proportion of patients who remained on the index
treatment, and the proportion of patients using any non-
biologic or biologic DMARD at the end of each month
during the 12-month study period were reported. No
comparative analyses were performed between samples.
As patients could have more than one type of treatment
change, the percentage of all changes does not always
add up to 100%.
The median time to the observed therapy change was
also reported. Median time to therapy change was calcu-
lated among patients who incurred the studied therapy
change as the number of days between the index date
and the date of the studied therapy change.
Results
Overall, 1,698 patients met the sample selection criteria
and initiated an oral nonbiologic DMARD on the index
date, with the majority being initiated on MTX (71%,
n = 1,217). Additionally, 3,263 patients met the sample
selection criteria and initiated a biologic DMARD treat-
ment on the index date (Figure 1).
Figure 1 Sample selection criteria results. aMTX users are a subgroup of the oral nonbiologic DMARD users. DMARD, disease-modifying
antirheumatic drug; MTX, methotrexate; NSAID, nonsteroidal anti-inflammatory drug; PsA, psoriatic arthritis.
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Patients’ average age was approximately 50 years, and a
slight majority (54%) was female (Table 1). Over 60% of
patients were seen by a rheumatologist during the baseline
period or at the index date, and approximately a quarter
were seen by a dermatologist. Average CCI was 0.47, 0.44,
and 0.52 for patients initiated on an oral nonbiologic
DMARD, MTX, and biologic DMARD therapy, res-
pectively. The most common comorbidities during the
baseline period were psoriasis (approximately 35%), hy-
pertension (approximately 20%), diabetes (approximately
11%), and hypothyroidism (approximately 6%) (Table 1).
During the baseline period, 58% of patients initiated
on an oral nonbiologic DMARD were treated with an
NSAID, and 32% received oral corticosteroids. For
patients initiated on a biologic DMARD, 59% used a
nonbiologic DMARD during the baseline period, 51% an
NSAID, and 32% an oral corticosteroid. Approximately
10% of patients initiated on an oral nonbiologic DMARD
used an oral corticosteroid at the index date, while
approximately 46% of patients initiated on a biologic
DMARD used a nonbiologic DMARD and/or an oral
corticosteroid at the index date (35% used a biologic
DMARD and a nonbiologic DMARD, 5% used a biologicDMARD and an oral corticosteroid, and 6% used a
biologic DMARD, a nonbiologic DMARD, and an oral
corticosteroid). These numbers included patients who
initiated a nonbiologic DMARD and/or an oral cortico-
steroid at the index date or prior to the index date and
whose prescription overlapped with the index date.
For patients initiated on an oral nonbiologic DMARD,
the average total healthcare cost per patient over the
6-month baseline period was $5,377, while the same
period yielded an average cost of only $2,476 for patients
initiated on a biologic DMARD.
Therapy changes
Oral nonbiologic DMARD users
Overall, 69% of patients initiated on an oral nonbiologic
DMARD and 65% of patients in the MTX subgroup had
at least one therapy change during the course of the
12-month study. The median time to the first therapy
change was 85 days for patients initiated on an oral non-
biologic DMARD and 93 days for the MTX subgroup.
Among patients who had at least one therapy change,
47% of the oral nonbiologic DMARD users and 55% of
the patients in the MTX subgroup used a biologic
DMARD at some point during the 12-month study







N = 1,698 N = 1,217 N = 3,263
Demographics
Age, mean (SD) 49.8 (12.5) 49.8 (12.3) 49.4 (11.6)
Female, number (%) 927 (54.6) 657 (54.0) 1,736 (53.2)
Combination of treatment with another nonbiologic DMARD and/or oral
corticosteriod at the index date
168 (9.9) 138 (11.3) 1,512 (46.3)
During the 6-month pre-index period, including the index date
Specialist encounter, number (%)
Rheumatologist or Dermatologist 1,175 (69.2) 841 (12.3) 2,347 (71.9)
Rheumatologist 1,055 (62.1) 755 (62.0) 2,008 (61.5)
Dermatologist 384 (22.6) 271 (22.3) 896 (27.5)
During the 6-month pre-index period
Comorbiditiesb,c, number (%)
Hypertension 364 (21.4) 260 (21.4) 670 (20.5)
Diabetes 175 (10.3) 129 (10.6) 376 (11.5)
Hypothyroidism 114 (6.7) 81 (6.7) 200 (6.1)
Chronic pulmonary disease 111 (6.5) 72 (5.9) 176 (5.4)
Deficiency anemia 77 (4.5) 62 (5.1) 164 (5.0)
Psoriasis 545 (32.1) 420 (34.5) 1,194 (36.6)
Charlson comorbidity index, mean (SD) 0.47 (0.87) 0.44 (0.84) 0.52 (0.88)
Prior use of NSAID, oral corticosteriod, and nonbiologic DMARDs, number (%)
NSAIDs 991 (58.4) 701 (57.6) 1,665 (51.0)
Oral corticosteriods 550 (32.4) 396 (32.5) 1,036 (31.7)
Nonbiologic DMARDs 0 (0.0) 0 (0.0) 1,938 (59.4)
aThe baseline period consisted of the 6-month period prior to the index date. bElixhauser A, Steiner C, Kruzikas D. Comorbidity Software. January 2004. HCUP
Methods Series Report #2004-1. Online, February 6, 2004. US Agency for Healthcare Research and Quality: pp 12-15 [16]. c Only mental and physical comorbidities
where at least one of the reported cohorts had a prevalence of ≥5% were reported in the table. DMARD, disease-modifying antirheumatic drugs; MTX,
methotrexate; number, number of patients; NSAID, nonsteroidal anti-inflammatory drug.
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was 138 days for oral nonbiologic DMARD users and
135 days for patients in the MTX subgroup (Figure 2).
Among patients who had at least one therapy change,
83% discontinued treatment (median time: 89 days), 29%
switched (median time: 113 days), and 25% had a therapy
add-on (median time: 116 days) (Figure 3). Among pa-
tients who switched therapies, 64% switched to a biologic
DMARD (median time: 141 days), and 46% switched to
another nonbiologic DMARD (median time: 111 days).
Among patients who had a therapy add-on, 76% of pa-
tients added-on with a biologic DMARD (median time:
119 days), and 28% added-on with another nonbiologic
DMARD (median time: 94 days).
Among the patients in the MTX subgroup who had at
least one therapy change, 79% discontinued (median
time: 96 days), 30% had a therapy add-on (median time:
122 days), and 25% switched (median time: 132 days)
(Figure 3). Among the patients who switched therapies,73% switched to a biologic DMARD (median time:
139 days), and 33% switched to another nonbiologic
DMARD (median time: 161 days). Among the patients
who had a therapy add-on, 84% had a biologic DMARD
added (median time: 122 days), and 19% had another
non-biologic DMARD added (median time: 125 days).
Among patients initiated on an oral nonbiologic
DMARD, 80%, 62%, 43%, and 31% of the patients were
still continuously treated with the index therapy by the
end of the first, third, sixth, and twelfth month following
the index date, respectively (Figure 4). Further, 88%,
77%, 66%, and 56% were still continuously treated with
any nonbiologic or biologic DMARD at the end of the
first, third, sixth, and twelfth month following the index
date, respectively (Figure 5).
Biologic DMARD users
Overall, 46% of the patients had at least one therapy
change during the course of the 12-month study period.
Figure 2 Biologic use in oral nonbiologic DMARD patients and in MTX patients. aThis refers to oral nonbiologic DMARD users. bMTX users
are a subgroup of the oral nonbiologic DMARD users. cThese categories presented are mutually exclusive. dThese categories presented are
mutually exclusive. DMARD, disease-modifying antirheumatic drug; MTX, methotrexate.
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110 days. All patients who had at least one therapy
change discontinued the index biologic treatment at
some point during the 12-month study period (median
time: 122 days). Additionally, among patients who had
at least one therapy change, 25% of patients switched
(median time: 173 days), and 7% of patients had a the-
rapy add-on with a nonbiologic DMARD (median time:Figure 3 Detailed schematic of therapy changes in oral nonbiologic D
users. bMTX users are a subgroup of the oral nonbiologic DMARD users. cThes
presented are not mutually exclusive. eThese categories presented are not mu
MTX, methotrexate.59 days). Among patients who switched therapies, 92%
of the patients switched to another biologic DMARD
(median time: 181 days), and 11% switched to a non-
biologic DMARD (median time: 92 days) (Figure 6).
Moreover, 92%, 80%, 67%, and 54% of patients were still
continuously treated with the index therapy by the end
of the first, third, sixth, and twelfth month following the
index date, respectively (Figure 4), and approximatelyMARD patients and in MTX. aThis refers to oral nonbiologic DMARD
e categories presented are not mutually exclusive. dThese categories
tually exclusive. DMARD, disease-modifying antirheumatic drug;
Figure 4 Patients remaining on the index therapy by month. DMARD, disease-modifying antirheumatic drug; MTX, methotrexate.
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with a nonbiologic or biologic DMARD at the end of the
first, third, sixth, and twelfth month following the index
date, respectively (Figure 5).
Sensitivity analyses
Consistent results were found from the two sensitivity
analyses performed on data subsets that (1) did not
exclude patients with AS and (2) excluded patients with
RA led to consistent findings (results not reported).
Among all patients initiated on an oral nonbiologic
DMARD, 51% were calculated to have discontinued their
index therapy when using a 90-day treatment gap defi-
nition for discontinuation, as opposed to the 58% thatFigure 5 Patients remaining on any PsA-related therapy by month. In
considered as any PsA-related therapy. DMARD, disease-modifying antirheudiscontinued in the study analysis with a 60-day treat-
ment gap (results not reported). Additionally, among the
entire subgroup of patients initiated on MTX, 44% dis-
continued their index therapy in the 90-day treatment
gap analysis, as opposed to the 52% reported using a
60-day treatment gap. Further, among all patients that
were initiated on a biologic DMARD, 36% discontinued
their index therapy in the 90-day discontinuation gap
analysis, as opposed to the 46% identified using a 60-day
treatment gap (results not reported).
Discussion
This large, retrospective study described nonbiologic
and biologic DMARD treatment patterns in patientsthis figure, only nonbiologic DMARDs and biologic DMARDs are
matic drug; MTX, methotrexate; PsA, psoriatic arthritis.
Figure 6 Detailed schematic of therapy changes in biologic DMARD patients. aThese categories presented are not mutually exclusive.
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US-health plans and self-insured employers. Outcome
measures included changes documented from the initial
DMARD therapy over a 1-year period following treat-
ment initiation, including treatment discontinuations,
switches, and therapy add-ons. Recent studies have ana-
lyzed treatment patterns for specific biologic DMARDs
(adalimumab, etanercept, and infliximab) in patients
with RA, psoriasis, PsA, or AS, or in patients with PsA
alone [17,18]. Other studies also examined treatment re-
sponse to different patterns of treatments (for example,
investigating the effectiveness of switching to a second
TNFi) or the effect of concomitant MTX on treatment
response and persistence. However, little is known about
treatment patterns when patients are newly initiated on a
DMARD, stratified by nonbiologic and biologic DMARDs.
This study differs from those reported previously in the
literature as it investigates treatment patterns in PsA pa-
tients following the initiation of nonbiologic and biologic
DMARDs by separately grouping all patients initiated on
various nonbiologic DMARDs together in one group,
while pooling all patients initiated on various biologic
DMARDs together in another study group.
The results revealed that in a sample of 1,698 com-
mercially insured PsA patients newly initiated on an oral
nonbiologic DMARD, mainly MTX, patient persistence
with treatment was generally low and relatively brief.
Almost 70% of these patients had at least one therapy
change within the first year, with the initial change
generally occurring within the first 3 months after theindex date. Moreover, among patients who had at least
one therapy change, the majority (83%) discontinued
treatment after 3 months. Of those patients who switched
treatment or had a therapy add-on, most switched to or
added on a biologic DMARD. Similar to the findings in
this study, investigators have shown that, in patients with
RA, treatment persistence with nonbiologic DMARDs -
mainly MTX, chloroquine, and sulfasalazine - erodes
rapidly and progressively over time, with persistence rates
declining from approximately 70% at one year to 34% at
2 years [19]. In the current analysis, only 31% of the
patients persisted uninterruptedly with their initial non-
biologic DMARD therapy after one year, and slightly more
than half (56%) persisted uninterruptedly with any non-
biologic or biologic DMARD after one year.
For the patients treated with a biologic DMARD,
more than half (54%) persisted with their initial therapy
throughout the entire 1-year study period and almost
three-quarters (70%) remained on PsA therapy. Of the pa-
tients who switched therapy, the vast majority (92%) were
treated with another biologic DMARD. These results sug-
gest that patients initiated on a biologic DMARD tend to
remain on this form of therapy and do not switch back to
nonbiologic DMARDs. In addition, very few patients (7%)
had a therapy add-on with a nonbiologic DMARD. Other
investigators using retrospective data analyses have also
found relatively robust treatment persistence with the use
of biologic DMARDs in the treatment of PsA [17,18,20].
In these studies, one-year treatment persistence rates for
biologic DMARDs ranged from approximately 50% to
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studies, relatively high rates of persistence after one year
were associated with correspondingly high treatment-
response rates [20].
In real-world clinical practice, patients may change the-
rapies for different reasons. Although reasons for the low
rate of persistence with the initial DMARD therapy were
not available in the database, a potential reason for the-
rapy change may include the lack of effectiveness of the
DMARD at controlling patient symptoms and slowing
disease progression. Patients might also switch or discon-
tinue treatment due to tolerability or safety issues, or oc-
currence of adverse events, or discontinue treatment due
to disease remission or pregnancy. PsA patients may also
switch due to persistent activity of psoriasis rather than
PsA Other potential reasons may also include changes in
the reimbursement policy of healthcare plan or the
involvement of multiple physicians in the management of
PsA or other economic reasons. Moreover, many health-
care insurance plans require, for reimbursement purposes,
that patients first use at least one to two nonbiologic
DMARDs prior to using a biologic DMARD. This may
also contribute to the high rates of therapy switch to/
add-on of a biologic DMARD among patients initiated on
a nonbiologic DMARD. However, further analyses would
be warranted to confirm the main reasons for treatment
changes in PsA patients.
Study limitations
Our study was subject to the common limitations of
retrospective, observational studies based on healthcare
claims data. For instance, the severity of PsA symptoms
varied among individuals and could presumably affect a
patient’s treatment profile. However, claims databases
record diagnostic and procedural codes only and do not
reveal disease severity. Moreover, claim data typically
report diagnoses/procedures associated with the health-
care services provided for reimbursement purposes and
might underestimate patients’ other comorbid condi-
tions (not related to diagnoses received or procedures
performed) that are not systematically reported by the
physician. For example, in this study, there were only
32% of nonbiologic DMARD patients and 37% of bio-
logic DMARD patients who had a recorded diagnosis for
psoriasis. Similarly, only 1.6% of biologic DMARD pa-
tients and 2.3% of nonbiologic DMARD patients had a re-
corded diagnosis for obesity during the baseline period.
This suggests an underestimation of the prevalence of
these conditions. Further, claims databases do not provide
any information regarding the underlying reasons for the-
rapy changes. This study also was limited to a 12-month
period following the initiation of a DMARD. Further
analyses are warranted to observe treatment patterns over
a longer period of time. In addition, the influence ofcorticosteroid use on treatment patterns was not assessed.
Moreover, the study covered the period from 2005 to
2009, an interval when the use of biologic DMARDs for
PsA was still relatively new. Patterns of biologic DMARD
use may have changed in more recent years. Finally, when
performing claims data analyses, it may be difficult to en-
sure that the selected PsA patients have been accurately
diagnosed for PsA, especially as some of the core symp-
toms of PsA also are known to manifest in AS or RA. The
two sensitivity analyses around these topics led to findings
consistent with the main analysis.
Conclusion
This retrospective analysis, based on large and geogra-
phically broad US health plan data, provides real-world
insight into nonbiologic and biologic DMARD treatment
patterns in patients with PsA. The results suggest that the
majority of patients treated with nonbiologic or biologic
DMARDs change therapy early after treatment initiation,
with many switching to a biologic DMARD therapy or, in
nonbiologic users, adding on a biologic DMARD. Among
the initial biologic DMARD patients who end up swit-
ching therapies, the majority do so with another biologic
DMARD (as opposed to a non-biologic DMARD). These
results suggest that a better understanding of factors re-
lated to early DMARD treatment changes in PsA patients
are needed to optimize treatment.
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